PCI vs CABG: What the Evidence Actually Shows

The evidence is unambiguous: any form of alcohol predisposes to cardiac dysfunction. Traditional drinks have been examined alongside commercially available alcohol in studies, and the myth that red wine protects the heart has been comprehensively debunked. Chronic alcohol consumption damages the heart, full stop. Whether someone chooses to drink socially is a personal decision, but scientifically there is no basis for recommending any alcohol for cardiac health.

You do not manage it — you accept it, because that is your best option to open the coronary artery blockage. The bleeding risk is only a problem in a living patient. If the patient dies from a myocardial infarction for lack of intervention, there is no bleeding to manage.

It should be started at the lowest possible dose — half a tablet, 25mg once daily, titrated over a week to 50mg, then 100mg, not typically exceeding 100mg once daily or 50mg twice daily. The primary indication is ejection fraction below 45% with elevated NT-proBNP. In a patient with ejection fraction below 35% and high NT-proBNP, it should be initiated at the lowest dose and titrated carefully upward.

In Africans and Asians, coronary artery disease is largely driven by genetic predisposition. In Caucasians, the predominant driver is sedentary lifestyle combined with diet — high-fat foods, alcohol, physical inactivity — which more than compensates for their lesser genetic predisposition. Surgical outcomes are comparable worldwide, with success rates upward of 90% and combined morbidity and mortality after CABG around 5 to 7% regardless of country. But the numbers in Asia and Africa are hugely underrepresented — if one million cardiac deaths annually in sub-Saharan Africa is the current reported figure, the true number with adequate diagnostic infrastructure would likely be closer to three million.

The traditional Indian vegetarian population was genuinely following something close to this diet. What changed was cooking oil. Industrial cooking oils were repackaged and marketed under omega fatty acid branding — omega-3, then omega-6, now omega-9 — persuading consumers to abandon traditional cooking fats like mustard oil and olive oil for artificially processed, packaged products whose health claims aren't supported by meaningful clinical evidence. If the population simply returned to traditional cooking oils, it would likely cut the cardiac disease burden significantly. The pyramid isn't the problem; the oil in the pan is.

SYNTAX, NOBLE and PRECOMBAT trials consistently favour CABG: fewer adverse events at one year, lower rates of revascularisation from stent occlusion or graft failure, and greater long-term durability, despite higher 30-day morbidity.

A score of 0 to 23 is considered low risk, 23 to 32 moderate, and above 32 high; the higher the score, the worse the coronary anatomy and the more a patient benefits from CABG over PCI.

When the SYNTAX score is low, when an acute problem needs an acute solution, or when the patient is frail and elderly.

No; every trial free of serious industry involvement has been a non-inferiority trial at best, showing only that PCI is not inferior to CABG, never that it is superior.